Trials / Unknown
UnknownNCT01819402
Pioglitazone Decreases Visceral Fat Metabolism
Effects of Pioglitazone on Visceral Fat Metabolic Activity
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Kurume University · Academic / Other
- Sex
- All
- Age
- 35 Years – 58 Years
- Healthy volunteers
- Accepted
Summary
Excess visceral fat is associated with chronic systemic inflammation and cardiovascular complications. Pioglitazone has been reported to variably influence visceral fat volume, but it its effect on metabolic activity of the visceral fat remains uncharacterized. To evaluate the effect of pioglitazone on glucose metabolism of fat tissue by using 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT) imaging.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pioglitazone vs Glimepiride |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2013-04-01
- First posted
- 2013-03-27
- Last updated
- 2013-03-27
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01819402. Inclusion in this directory is not an endorsement.